ClinicalTrials.gg
CompletedNCT00378690ICELANDUpdated Jun 4, 2014

A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD

A Phase 3 interventional study of leuprorelin acetate in Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 71 sites in 10 countries. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-04.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
706
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
5th of 69
706 · median 77
Started
2006
the only one that year
Phase 3
26 of 70
3 open now
Registered
10th of 70
by date

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 5th largest by enrollment of the 69 interventional ones that give a count, is the only one that started in 2006, is one of 26 in phase 3, and was the 10th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Phase IIIb, Open-label, randomized, controlled multi-centre study. Induction therapy phase for 6 months where all subjects receive 2 ELIGARD depot injections. Those subjects with hormone responsive prostate cancer will be randomized and will receive either intermittent or continuous ELIGARD treatment for 36 months. Following this treatment period, subjects will enter a long-term follow-up period for 48 months.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Prostate Specific Antigen
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At study entry (visit 1):

  • Written
  • Male subjects aged >=18 and \<80 years old
  • Locally advanced (stage T3 or T4) prostate cancer or Relapsing prostate cancer following radical prostatectomy or,Relapsing prostate cancer following radiotherapy
  • Gleason score of >=6
  • performance status of 0-2.
  • at least 5 years

At randomization (visit 4):

  • Two successive decreasing serum PSA levels \<=1 ng/ml

Exclusion criteria

Exclusion Criteria:

At study entry (visit 1):

  • Any suspected second primary tumors
  • Evidence of disease
  • Other within the last 5 years except
  • Acute spinal cord compression, uni- or bilateral ureteric obstruction
  • Any concurrent biological response modifier therapy
  • Concurrent chemotherapy
  • Less than 1 year since any prior or adjuvant hormonal therapy
  • Less than 6 months since prior 5-alpha reductase inhibitor treatment
  • Other concurrent hormonal therapy
  • Any concurrent radiotherapy
  • Testosterone at screening \<= 1.7 mM or 50 ng/dL
  • elevation of serum creatinine or liver enzymes
  • to GnRH or other GnRH analogues or leuprorelin acetate
  • Hypersensitivity to CASODEXâ 50 mg.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
706 participants (actual)

Study arms

  • Active comparator
    Continuous Androgen Deprivation (CAD)

    Drug: leuprorelin acetate

  • Experimental
    Intermittent Androgen Deprivation (IAD)

    Drug: leuprorelin acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Time to PSA progression

    Time frame: 3 Years

Secondary outcomes

  1. Overall survival

    Time frame: 5 Years

  2. World Health Organization/Eastern Cooperative Oncology Group (WHO/ECOG) performance status

    Time frame: 3 Years

  3. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and QLQ-PR25

    Time frame: 3 Years

  4. Time to serum testosterone > 50 ng/dL

    Time frame: 3 Years

  5. Change in progression biomarkers (some sites)

    Time frame: 3 Years

07

Study locations

71 sites
  • Brussel, Belgium
  • Bruxelles, 1070, Belgium
  • Bruxelles, 1200, Belgium
  • Leuven, B-3000, Belgium
  • Liege, 4000, Belgium
  • Bmo, 65691, Czech Republic
  • Jablonec nad Nisou, 46660, Czech Republic
  • Olomouc, 7521, Czech Republic
  • Usti nad Labem, 40113, Czech Republic
  • Joensuu, FIN-80210, Finland
  • Tampere, FIN-33521, Finland
  • Avignon, 84000, France
  • Bordeaux, 33073, France
  • Brest, 29609, France
  • Caen-Cedex, 14033, France
  • Cergy-Pontoise, 95301, France
  • Grenoble, 38043, France
  • Marseille, 13915, France
  • Nantes, 44093, France
  • Paris, 75007, France
  • Paris, 75014, France
  • Paris, 94275, France
  • Pierre-Benite, 69310, France
  • Ploemeur, 53275, France
  • Rouen, 76031, France
  • Suresnes, 92151, France
  • Toulon, 83000, France
  • Toulouse, 31054, France
  • Bad Neuenaher, 53474, Germany
  • Bautzen, 02625, Germany
  • Dresden, 01307, Germany
  • Dresden, 01324, Germany
  • Hagenow, 19230, Germany
  • Halle/Saale, 06132, Germany
  • Hettstedt, 06333, Germany
  • Leipzig, 04105, Germany
  • Neustadt i. Sachsen, 01844, Germany
  • Trier, 54290, Germany
  • Budapest, 1106, Hungary
  • Kaposvar, 7400, Hungary
  • Nyiregyhaza, 4400, Hungary
  • Szolnok, 5000, Hungary
  • Tatabanya, 2800, Hungary
  • Veszprem, 8200, Hungary
  • Desio, Milano 20033, Italy
  • Ancona, Italy
  • Bari, Italy
  • Bergamo, 24128, Italy
  • Bologna, 40138, Italy
  • Chieti, Italy
  • Messina, Italy
  • Milano, Italy
  • Parma, 43100, Italy
  • Roma, 00189, Italy
  • Moscow, 115478, Russian Federation
  • Moscow, 125101, Russian Federation
  • Moscow, 125284, Russian Federation
  • St. Petersburg, 198013, Russian Federation
  • St. Petersburg, 198255, Russian Federation
  • Martin, 03659, Slovakia
  • Skalica, 90982, Slovakia
  • Trencin, 91101, Slovakia
  • Alcorcon, Madrid 28922, Spain
  • Barcelona, 8003, Spain
  • Barcelona, 8035, Spain
  • Barcelona, 8036, Spain
  • Granada, Spain
  • La Coruna, Spain
  • Madrid, 28041, Spain
  • Madrid, Spain
  • Valencia, 46009, Spain
08

References and documents

Publications

  • Tombal B, Cornel EB, Persad R, Stari A, Gomez Veiga F, Schulman C. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. J Urol. 2017 Nov;198(5):1054-1060. doi: 10.1016/j.juro.2017.05.072. Epub 2017 May 25. PubMed 28552710 ↗
  • Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gomez Veiga F, Baskin-Bey E, Lopez B, Tombal B. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). Eur Urol. 2016 Apr;69(4):720-727. doi: 10.1016/j.eururo.2015.10.007. Epub 2015 Oct 29. PubMed 26520703 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Jun 2011 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2006
First posted
Sep 21, 2006
Start
Mar 2006
Primary completionActual
Jun 2011
CompletionActual
Dec 2012
Last update
Jun 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00378690
Responsible party
Sponsor
First posted
Sep 21, 2006
Start date
Mar 2006
Primary completion
Jun 2011
Completion
Dec 2012
Last update
Jun 4, 2014

Study contacts

Central Contact
study director · Medical Affairs Europe, Astellas Pharma Europe Limited Hillswood Drive

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion